Establishment of a model of penicillin-resistant Streptococcus pneumoniae pneumonia in healthy CBA/J mice

Takashima, Koji; Tateda, Kazuhiro; Matsumoto, Tetsuya; Ito, Takeshi; Iizawa, Yuji; Nakao, Masao; Yamaguchi, Keizo

doi:10.1099/00222615-45-5-319

Cited by 25 publications

(20 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The infection produced in the 24-h BAP model was confined to the interior of the airway, with no notable tissue disruption and minimal inflammatory response [14]. Importantly, the epithelial lining of the airspace remained intact and largely unperturbed.…”

Section: Resultsmentioning

confidence: 99%

Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact

et al. 2005

View full text Add to dashboard Cite

The lipopeptide daptomycin has been approved for use in skin and skin-structure infections but has failed to meet statistical noninferiority criteria in a clinical trial for severe community-acquired pneumonia. Daptomycin exhibited an unusual pattern of activity in pulmonary animal models: efficacy in Staphylococcus aureus hematogenous pneumonia and inhalation anthrax but no activity against Streptococcus pneumoniae in simple bronchial-alveolar pneumonia. Daptomycin was shown to interact in vitro with pulmonary surfactant, resulting in inhibition of antibacterial activity. This effect was specific to daptomycin and consistent with its known mechanism of action. This represents the first example of organ-specific inhibition of an antibiotic.

show abstract

Section: Resultsmentioning

confidence: 99%

Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Evidence for the existence and efficacy of phosphocholine antibodies indicates that they may play an important role in the innate immune response (11,17,32). However, a number of authors have indicated that the genetic background of CBA mice renders this murine strain susceptible to pneumococcal infection and that this finding cannot be accounted for by the xid locus only but must involve the abrogating effect of hitherto unknown genes (8,10,26).…”

mentioning

confidence: 99%

Role of Genetic Resistance in Invasive Pneumococcal Infection: Identification and Study of Susceptibility and Resistance in Inbred Mouse Strains

et al. 2001

View full text Add to dashboard Cite

From a panel of nine inbred mice strains intranasally infected with Streptococcus pneumoniae type 2 strain, BALB/c mice were resistant and CBA/Ca and SJL mice were susceptible to infection. Further investigation revealed that BALB/c mice were able to prevent proliferation of pneumococci in the lungs and blood, whereas CBA/Ca mice showed no bacterial clearance. Rapidly increasing numbers of bacteria in the blood was a feature of CBA/Ca but not BALB/c mice. In the lungs, BALB/c mice recruited significantly more neutrophils than CBA/Ca mice at 12 and 24 h postinfection. Inflammatory lesions in BALB/c mice were visible much earlier than in CBA/Ca mice, and there was a greater cellular infiltration into the lung tissue of BALB/c mice at the earlier time points. Our data suggest that resistance or susceptibility to intranasal pneumococci may have an association with recruitment and/or function of neutrophils.

show abstract

“…Five-week-old male CBA/J specific-pathogen-free mice (body weight, 20 g) were purchased from Charles River Japan. The CBA/J mouse model of PRSP pneumonia has been described previously (19,21). All mouse experiments were performed according to the guidelines of the Laboratory Animal Center for Biomedical Research, Nagasaki University School of Medicine.…”

Section: Methodsmentioning

confidence: 99%

In VivoEfficacy of a New Quinolone, DQ-113, against Streptococcuspneumoniae in a MouseModel

Otsu

Yanagihara

Fukuda

et al. 2003

Antimicrob Agents Chemother

View full text Add to dashboard Cite

DQ-113 is a new quinolone with potent activity against gram-positive pathogens. The in vivo activity of DQ-113 against Streptococcus pneumoniae was compared with those of gatifloxacin and ciprofloxacin in a mouse model. For this purpose, two strains of S. pneumoniae were used: penicillin-susceptible S. pneumoniae (PSSP) and penicillin-resistant S. pneumoniae (PRSP). The survival rates of mice infected with PSSP and PRSP at 14 days after infection were 80% in the DQ-113-treated group and 0 to 10% in the other three groups. In murine infections caused by PSSP, the 50% effective doses (ED 50 s) of DQ-113, gatifloxacin, and ciprofloxacin were 6.0, 41.3, and 131.6 mg/kg, respectively. Against PRSP-caused pneumonia in mice, the ED 50 s of DQ-113, gatifloxacin, and ciprofloxacin were 7.6, 64.7, and 125.9 mg/kg, respectively. Compared with the other drugs, DQ-113 showed excellent therapeutic efficacy and eradicated viable bacteria in both PSSP-and PRSP-infected mice. The means ؎ standard errors of the means of viable bacterium counts in the lungs of gatifloxacin-treated, ciprofloxacin-treated, and untreated control mice infected with PSSP were 2.91 ؎ 0.34, 3.13 ؎ 0.48, and 3.86 ؎ 0.80 log 10 CFU/ml, respectively. The same counts in mice infected with PRSP treated with the same three agents were 6.57 ؎ 0.99, 6.54 ؎ 0.40, and 7.17 ؎ 0.43 log 10 CFU/ml, respectively. DQ-113 significantly decreased the number of viable bacteria in the lungs compared with gatifloxacin and ciprofloxacin. Of the drugs analyzed, the pharmacokinetic-pharmacodynamic parameter of area under the concentration-time curve (AUC)/MIC ratio for DQ-113 was significantly higher than those for gatifloxacin and ciprofloxacin. Our results suggest that DQ-113 has potent in vivo efficacy against both PSSP and PRSP.

show abstract

Establishment of a model of penicillin-resistant Streptococcus pneumoniae pneumonia in healthy CBA/J mice

Cited by 25 publications

References 9 publications

Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact

Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact

Role of Genetic Resistance in Invasive Pneumococcal Infection: Identification and Study of Susceptibility and Resistance in Inbred Mouse Strains

In VivoEfficacy of a New Quinolone, DQ-113, against Streptococcuspneumoniae in a MouseModel

Contact Info

Product

Resources

About